摘要
目的:评价氟马替尼联合多药化疗在费城染色体阳性急性淋巴细胞白血病(Philadelphia chromosome-positive acute lymphoblastic leukemia,Ph^(+)ALL)患者中的疗效和安全性。方法:回顾性分析南昌大学第一附属医院2019年12月至2022年2月收治的25例行氟马替尼联合CALLG-2008化疗方案治疗的成人Ph^(+)ALL患者的临床资料,分析其疗效和安全性。结果:25例患者中,21例(84%)患者于初次诱导期联合氟马替尼,4例(16%)患者于第1个疗程诱导结束后联合氟马替尼。患者化疗28天、3个月和6个月的完全缓解(complete response,CR)率分别为88%、91.67%和90.48%;主要分子学反应(major molecular response,MMR)率分别为68%、79.17%和80.95%;完全分子学反应(complete molecular response,CMR)率分别为60%、75%和80.95%。中位随访时间180(75.6~458.1)天,随访时总生存(overall survival,OS)率为82.61%,无复发生存(recurrence-free survival,RFS)率为73.91%。氟马替尼用药过程中,有22例(88%)患者出现Ⅳ度骨髓抑制,非血液学不良反应主要有腹泻、转氨酶升高、疲乏、恶心等,经对症治疗后均可好转。结论:氟马替尼联合多药化疗治疗Ph^(+)ALL患者安全有效。
Objective:To evaluate the efficacy and safety of flumatinib combined with multi-agent chemotherapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia(Ph^(+)ALL).Methods:The retrospective analysis involved 25 patients with Ph^(+)ALL treated with flumatinib combined with CALLG-2008 chemotherapy at The First Affiliated Hospital of Nanchang University from December2019 to February 2022.The efficacy and safety of the treatment were statistically analyzed.Results:Among the 25 patients,21(84%)and 4(16%)patients were treated with flumatinib during and after the first induction period,respectively.Complete response(CR)rates at 28days,3 months,and 6 months were 88%,91.67%,and 90.48%,respectively.The respective major molecular response(MMR)rates were68%,79.17%,and 80.95%.The respective complete molecular response(CMR)rates were 60%,75%,and 80.95%.The patients were followed-up with a median follow-up time of 180 days(range,75.6-458.1 days).The overall survival(OS)and recurrence-free survival(RFS)rates were 82.61%and 73.91%,respectively.During flumatinib treatment,22(88%)patients displayed gradeⅣmyelosuppression.The nonhematologic adverse events mainly included diarrhea,elevated transaminase,fatigue,and nausea.All adverse events improved after treatment.Conclusions:Flumatinib combined with multi-agent chemotherapy is safe and effective in the treatment of patients with Ph^(+)ALL.
作者
谭根梅
齐凌
纪德香
李菲
Genmei Tan;Ling Qi;Dexiang Ji;Fei Li(Department of Hematology,The First Affiliated Hospital of Nanchang University,Jiangxi Provincial Clinical Medical Research Center for Hematology,Nanchang 330006,China)
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2022年第17期886-891,共6页
Chinese Journal of Clinical Oncology
基金
江西省科技创新基地计划项目(编号:20212BCG74001)
中央引导地方科技发展专项-国家血液系统疾病临床医学研究中心江西分中心项目(编号:20211ZDG02006)资助。
关键词
费城染色体
急性淋巴细胞白血病
氟马替尼
Philadelphia chromosome(Ph)
acute lymphoblastic leukemia(ALL)
flumatinib
